The grant of the US patent for PYC38 may be a key milestone as management seeks to add value to the phylomer library. It is also extraordinarily interesting that Johnson and Johnson are signalled out in the same announcement as an example of Phylogica's collaborations in the intracellular space.
Is there a connection? Do we finally have a clue as to the nature of the collaboration with Johnson and Johnson? TBI - targeted by PYC38 - is a huge unmet market, albeit one that shareholders of NEU hope will soon be filled.
Pure speculation on my part but a light bulb lit up as I reflected upon the announcement. If a Big Pharma company was interested in acquiring a strategic interest in a junior biotech then they would require guarantees in relation to the IP. In the case of Phylogica, the IP would include US patents on key phylomer peptides. Probably nothing but just maybe.
PYC Price at posting:
3.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)